Check 35,000+ stocks against 26 valuation models and 37 quality factors

Emmessar Biotech & Nutrition Limited (524768) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Emmessar Biotech & Nutrition Limited ₹12.35, price ₹22.99, upside -46.3%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · IN

EB Thin data Sep 27, 2026

Emmessar Biotech & Nutrition Limited

524768 · BSE

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value ₹12.35 · Strongly overvalued (−46.3%)

✓Quality 67/100

!Weak Growth (revenue 5y −44.4 %/yr)

✓Solidly profitable · 12.8% net margin (TTM)

✓generates free cash flow

!Trails peers (5/13)

!Moderate moat 60/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear ₹10.15 to bull ₹12.96 Growth analysisrevenue history, year by year Quality 67/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Emmessar Biotech & Nutrition Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range ₹19.15 – ₹62.61 · fair‑value band ₹10.15 – ₹12.96 · the ₹22.99 price screens above the ₹12.35 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Emmessar Biotech & Nutrition in your weekly email

Every Wednesday you see whether Emmessar Biotech & Nutrition is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Emmessar Biotech & Nutrition Limited, a healthcare company, manufactures and markets healthcare and nutritional products in India and internationally. It operates through Healthcare, Fine Chemicals, and Rent on Lease Land segments. The company offers bone care, general health, muscle care, pain relief, sexual health, skin care, and skin cure products. The company was formerly known as Emmessar Chemical Industries Ltd. and changed its name to Emmessar Biotech & Nutrition Limited in April 2000. Emmessar Biotech & Nutrition Limited was founded in 1992 and is headquartered in Mumbai, India.

Stock analysis

Emmessar Biotech & Nutrition Limited (524768) currently trades at ₹22.99, while our model-based Fair Value estimate is ₹12.35, 46.3% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹14.50 per share, and 0 of the 15 models we run sit above the ₹22.99 price.

Bear case: the Multiples group reads lowest at ₹2.60, and 15 of the 15 models stay below the price. Evidence for this calculation is low.

Scenario range: ₹10.15 (bear) to ₹12.96 (bull), the price of ₹22.99 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Emmessar Biotech & Nutrition Limited reported revenue of ₹3.7M in FY2026 versus ₹3.6M in FY2022, a compound +0.4%/yr. Reported net income was ₹4.4M in FY2026, compounding −2.1%/yr from FY2022.

Key figures

Market cap ₹115M (≈ $1.2M) · P/E ratio 19.9 · P/S ratio 23.4 · EPS (TTM) ₹0.7660 · Net margin 118% · Return on assets (EBIT) −12.5% · Operating margin 17.3% · Revenue growth (YoY) −78.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −46%, 524768 screens richer than that median.

Fair Value models

Bear ₹10.15 Fair Value ₹12.35 Bull ₹12.96

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.3903 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF ₹4.86 ₹6.61 ₹9.76 78

Growth DCF ₹5.06 ₹6.75 ₹9.55 76

Owner Earnings ₹9.88 ₹13.47 ₹19.91 74

All 15 models by family

DCF Models

FCF DCF ₹4.86 ₹6.61 ₹9.76 78

Owner Earnings ₹9.88 ₹13.47 ₹19.91 74

5Y Revenue Exit ₹2.84 ₹3.60 ₹4.69 71

5Y P/E Exit ₹9.38 ₹14.93 ₹21.52 68

10Y Revenue Exit ₹3.59 ₹4.21 ₹4.84 66

10Y P/E Exit ₹7.51 ₹11.06 ₹14.50 62

Earnings-Based

Graham-Dodd ₹5.93 ₹7.25 ₹8.16 67

Multiples

P/E Multiple ₹14.40 ₹19.19 ₹23.99 63

P/S Multiple ₹1.95 ₹2.60 ₹3.25 58

P/B Multiple ₹11.12 ₹14.83 ₹18.54 55

EV/Revenue ₹1.63 ₹2.29 ₹2.96 51

Asset-Based

NCAV (Graham) ₹8.12 ₹10.88 ₹16.24 51

Growth DCF

Growth DCF ₹5.06 ₹6.75 ₹9.55 76

Economic Profit

Residual Income ₹12.59 ₹12.97 ₹13.74 71

Growth Earnings

Growth-Adj P/E ₹10.15 ₹14.50 ₹18.85 67

Open the full fair value analysis →

Notify me when 524768 reaches fair value

Put 524768 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 67/100

Of which business quality 65 · Market factors (momentum, volatility) 31

Profitability 35

Margins and returns on capital today

Quality Growth 49

Are margins and returns improving?

Cashflow 77

Earnings quality: real cash, not paper profit

Fin. Strength 75

Balance sheet, leverage, solvency risk

Investment 78

Disciplined investing over empire-building

Low Volatility 57

Calm price path (market factor)

Momentum 26

Price trend over the last 3–12 months (market factor)

52W Momentum 11

Distance to the 52-week high (market factor)

Net Issuance 82

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100

Revenue is shrinking: the last year, the last three and the last five years are all negative.

Revenue growth 1 year

−39.3%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−28.6%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−44.4%

Start year 2021 (pandemic). Over 10 years: −15.4% a year

Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−10.8%

’14

’15

’16

’17

’18

’19

’20

’21

’23

’24

’25

’26

What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.

−14.7%

Earnings growth per share plus dividend.

Earnings per share, growth per year−14.7%

Dividend (yield on the price)0.0%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−14.7% vs −9.5%, slowing

Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → −392%

Start year 2021 (pandemic)

⚠ Revenue per share shrinking 21.3%/yr over ~7Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+9.2%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +4.9% a year for the price.

524768 screens overvalued: fair value 46% below the price. Compare with Merck KGaA →

Compare Emmessar Biotech & Nutrition Limited with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks

Beats the industry median on 5/12 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 67 · Top 25%

Fair Value upside −46.3% · Below median

Profitability

Return on assets 0.0% · Below median

Net margin (TTM) 12.8% · Above median

Operating margin (TTM) 17.3% · Top 25%

Growth and dividend

Revenue growth −78.3% · Bottom 25%

Dividend yield (TTM) 0.0% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 19.9× · Cheaper than median

P/B 1.42× · Cheaper than median

P/S (TTM) 3.83× · Pricier than median

P/FCF 44.8× · Priciest 25%

EV/EBITDA 20.0× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€134.45	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.90	$11.45	−39%
Teva Pharmaceutical Industries Limited TEVA	$39.31	$20.88	−47%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$70.30	$110.50	+57%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Emmessar Biotech & Nutrition Limited · Fair Value
₹12.35 −46%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/524768" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Emmessar Biotech &amp; Nutrition Limited · Fair Value</span><br><b style="font-size:20px">₹12.35</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−46%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Emmessar Biotech & Nutrition Limited Fair Value". https://www.fairvalue-calculator.com/stock/524768

Frequently asked questions

Is Emmessar Biotech & Nutrition Limited (524768) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of ₹12.35 versus a price of ₹22.99, about −46% upside (overvalued).

What is the fair value of 524768?

Our model-based fair value for Emmessar Biotech & Nutrition Limited is ₹12.35 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹22.99.

What is the quality score of 524768?

Emmessar Biotech & Nutrition Limited has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Emmessar Biotech & Nutrition Limited (524768)?

Our model-based price target is the fair value of ₹12.35 (as of Sep 27, 2026) from 15 valuation models. Cautious scenario ₹10.15, optimistic scenario ₹12.96. It is a calculation from audited fundamentals, not an analyst target.

What is the Emmessar Biotech & Nutrition Limited stock forecast for 2026?

Our models put fair value at ₹12.35, about −46% upside versus a price of ₹22.99 (overvalued). Cautious scenario ₹10.15, optimistic scenario ₹12.96. The calculation is refreshed regularly with new filings.

What growth is priced into Emmessar Biotech & Nutrition Limited (524768)?

For today's price to be fair in a discounted-cash-flow model, Emmessar Biotech & Nutrition Limited would have to grow free cash flow by +9.2 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -44.4 % per year. As of Sep 27, 2026.

What discount rate (WACC) does the fair value of 524768 use?

Our models discount Emmessar Biotech & Nutrition Limited at 10.9 %: a base by market capitalisation (nano), damped by beta 0.25, country premium for India. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Emmessar Biotech & Nutrition Limited that is +9.2 % per year a year over ten years, using the same discount rate (10.9 %) and the same formula as our fair value.

How much growth has Emmessar Biotech & Nutrition Limited (524768) delivered so far?

Over the past 5 years revenue at Emmessar Biotech & Nutrition Limited grew -44.4 % a year. The price currently implies +9.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Emmessar Biotech & Nutrition Limited (524768) growing?

The median revenue growth in the sector is +8.1 % a year. That is the yardstick for the growth priced into Emmessar Biotech & Nutrition Limited (+9.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Emmessar Biotech & Nutrition Limited (524768)?

The free-cash-flow yield on the price is 2.23 %: that much free cash flow Emmessar Biotech & Nutrition Limited produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Emmessar Biotech & Nutrition Limited (524768)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Emmessar Biotech & Nutrition Limited it is ₹12.35 per share (as of Sep 27, 2026), against a price of ₹22.99. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).

Is Emmessar Biotech & Nutrition Limited stock overvalued or undervalued in 2026?

As of Sep 27, 2026, 524768 trades above its calculated fair value: price ₹22.99, fair value ₹12.35, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 524768?

No. The price is what the market pays today (₹22.99); the fair value is what the company's own numbers justify (₹12.35). For Emmessar Biotech & Nutrition Limited the two are ₹10.64 per share apart. That gap is exactly why we show both numbers side by side.

How much is Emmessar Biotech & Nutrition Limited worth?

The market values Emmessar Biotech & Nutrition Limited at about ₹115M (market capitalisation, as of Sep 27, 2026). Per share that is ₹22.99; our models calculate a fair value of ₹12.35 per share.

What do the bullish and bearish scenarios say about 524768?

Our models span a range for Emmessar Biotech & Nutrition Limited: cautious scenario ₹10.15, base ₹12.35, optimistic ₹12.96 per share (as of Sep 27, 2026, price ₹22.99). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 524768?

Emmessar Biotech & Nutrition Limited trades at a price-to-earnings ratio of 19.9 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹12.35 is built from several models across several years. Other multiples: P/B 1.4, P/S 3.8, EV/EBITDA 20.0.

How far is 524768 from its 52-week high?

Emmessar Biotech & Nutrition Limited trades at ₹22.99, about 31% below its 52-week high of ₹33.50 and 15% above the low of ₹19.99 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹12.35 is for.

Which stocks are comparable to Emmessar Biotech & Nutrition Limited?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Emmessar Biotech & Nutrition Limited stock attractive at the current price?

The data as of Sep 27, 2026: price ₹22.99, calculated fair value ₹12.35 (−46%), Quality Score 67/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 524768 calculated?

We run Emmessar Biotech & Nutrition Limited through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹12.35, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Emmessar Biotech & Nutrition Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Emmessar Biotech & Nutrition Limited (524768)?

The closing price on Oct 1, 2026 was ₹22.99. Our model-based fair value is ₹12.35, about −46% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Emmessar Biotech & Nutrition Limited right now?

The price sits above even our optimistic bull case (₹12.96). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Emmessar Biotech & Nutrition Limited

How large is the market capitalisation of Emmessar Biotech & Nutrition Limited (524768)?

The market capitalisation of Emmessar Biotech & Nutrition Limited is ₹115M (≈ $1.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Emmessar Biotech & Nutrition Limited (524768)?

The price-to-sales ratio of Emmessar Biotech & Nutrition Limited is 23.4 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Emmessar Biotech & Nutrition Limited (524768)?

Earnings per share at Emmessar Biotech & Nutrition Limited are ₹0.7660 (price ÷ EPS = P/E 19.9). Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Emmessar Biotech & Nutrition Limited (524768)?

The net margin of Emmessar Biotech & Nutrition Limited is 118% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the EBIT return on assets of Emmessar Biotech & Nutrition Limited (524768)?

On an EBIT basis the return on assets of Emmessar Biotech & Nutrition Limited is −12.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Emmessar Biotech & Nutrition Limited (524768)?

The operating margin of Emmessar Biotech & Nutrition Limited is 17.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Emmessar Biotech & Nutrition Limited (524768)?

Revenue at Emmessar Biotech & Nutrition Limited is growing −78.3% versus a year earlier (3y avg −28.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Emmessar Biotech & Nutrition Limited (524768)?

Earnings per share at Emmessar Biotech & Nutrition Limited are growing −92.5% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Emmessar Biotech & Nutrition Limited (524768) carry?

The net debt of Emmessar Biotech & Nutrition Limited is ₹965K (fiscal year 2024, ≈ 0.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Emmessar Biotech & Nutrition Limited in the live analysis

One click puts Emmessar Biotech & Nutrition Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.